Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

NUCALA Powder for solution for injection (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Nucala 100 mg powder for solution for injection.

Qualitative and quantitative composition

Each vial contains 100 mg mepolizumab. After reconstitution, each ml of solution contains 100 mg mepolizumab. Mepolizumab is a humanised monoclonal antibody produced in Chinese hamster ovary cells by recombinant ...

Pharmaceutical form

Powder for solution for injection. Lyophilised white powder.

Therapeutic indications

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older (see section 5.1).

Posology and method of administration

Nucala should be prescribed by physicians experienced in the diagnosis and treatment of severe refractory eosinophilic asthma. Posology Adults and adolescents aged 12 years and older The recommended dose ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded in the patient file. Asthma exacerabations ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of mepolizumab. Increased levels of pro-inflammatory cytokines ...

Pregnancy and lactation

Pregnancy There is a limited amount of data (less than 300 pregnancy outcomes) from the use of mepolizumab in pregnant women. Mepolizumab crosses the placental barrier in monkeys. Animal studies do not ...

Effects on ability to drive and use machines

Nucala has no or negligible influence on the ability to drive and use machines.

Undesirable effects

Summary of the safety profile Adults and adolescents In clinical studies in subjects with severe refractory eosinophilic asthma, the most commonly reported adverse reactions during treatment were headache, ...

Overdose

Single doses of up to 1,500 mg were administered intravenously in a clinical trial to patients with eosinophilic disease without evidence of dose-related toxicities. There is no specific treatment for ...

Pharmacodynamic properties

Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases ATC code: R03DX09 Mechanism of action Mepolizumab is a humanised monoclonal antibody ...

Pharmacokinetic properties

Following subcutaneous dosing in patients with asthma, mepolizumab exhibited approximately dose-proportional pharmacokinetics over a dose range of 12.5 mg to 250 mg. Absorption Following subcutaneous administration ...

Preclinical safety data

As mepolizumab is a monoclonal antibody, no genotoxicity or carcinogenicity studies have been conducted. Animal toxicology and/or pharmacology Non-clinical data reveal no special hazards for humans based ...

List of excipients

Sucrose Sodium phosphate dibasic heptahydrate Polysorbate 80

Incompatibilities

This medicinal product must not be mixed with other medicinal products.

Shelf life

Shelf life: 4 years. After reconstitution: Chemical and physical stability of the reconstituted medicinal product have been demonstrated for 8 hours when stored below 30°C. From a microbiological point ...

Special precautions for storage

Store below 25°C. Do not freeze. Keep the vial in the outer carton in order to protect from light. For storage conditions after reconstitution of the medicinal product, see section 6.3.

Nature and contents of container

Clear, colourless 10 mL type I glass vial, with bromobutyl rubber stopper and a grey aluminium overseal with a plastic flip-cap containing 100 mg powder for solution for injection. Pack sizes: 1 vial ...

Special precautions for disposal and other handling

Reconstitution should be carried out under aseptic conditions. Instructions for reconstitution for each vial: Reconstitute the contents of the vial with 1.2 mL of sterile water for injections preferably ...

Marketing authorization holder

GlaxoSmithKline Trading Services Limited, Currabinny, Carrigaline, County Cork, Ireland

Marketing authorization number(s)

EU/1/15/1043/001 EU/1/15/1043/002

Date of first authorization / renewal of the authorization

Date of first authorisation: 02 December 2015

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: